Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets.
CHD1
ERG
WNT signaling
cell adhesion
junction plakoglobin
prostate cancer
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
21
01
2021
received:
02
01
2021
accepted:
22
01
2021
pubmed:
4
2
2021
medline:
8
4
2022
entrez:
3
2
2021
Statut:
ppublish
Résumé
Both oncogenic and tumor suppressor functions have been described for junction plakoglobin (JUP), also known as γ-catenin. To clarify the role of JUP in prostate cancer, JUP protein expression was immunohistochemically detected in a tissue microarray containing 11 267 individual prostatectomy specimens. Considering all patients, high JUP expression was associated with adverse tumor stage (P = 0.0002), high Gleason grade (P < 0.0001), and lymph node metastases (P = 0.011). These associations were driven mainly by the subset without TMPRSS2:ERG fusion, in which high JUP expression was an independent predictor of poor prognosis (multivariate analyses, P = 0.0054) and early biochemical recurrence (P = 0.0003). High JUP expression was further linked to strong androgen receptor expression (P < 0.0001), high cell proliferation, and PTEN and FOXP1 deletion (P < 0.0001). In the ERG-negative subset, high JUP expression was additionally linked to MAP3K7 (P = 0.0007) and CHD1 deletion (P = 0.0021). Contrasting the overall prognostic effect of JUP, low JUP expression indicated poor prognosis in the fraction of CHD1-deleted patients (P = 0.039). In this subset, the association of high JUP and high cell proliferation was specifically absent. In conclusion, the controversial biological roles of JUP are reflected by antagonistic prognostic effects in distinct prostate cancer patient subsets.
Identifiants
pubmed: 33533127
doi: 10.1002/1878-0261.12922
pmc: PMC8253102
doi:
Substances chimiques
Biomarkers, Tumor
0
FOXP1 protein, human
0
Forkhead Transcription Factors
0
JUP protein, human
0
Oncogene Proteins, Fusion
0
Repressor Proteins
0
gamma Catenin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1956-1969Informations de copyright
© 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Oncotarget. 2017 May 9;8(19):32270-32291
pubmed: 28416759
Nat Rev Urol. 2017 Nov;14(11):683-696
pubmed: 28895566
Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5420-5
pubmed: 15805189
J Clin Oncol. 2002 May 15;20(10):2417-28
pubmed: 12011119
Cancer Res. 2013 Oct 1;73(19):6068-79
pubmed: 23913826
Prostate. 2007 Sep 15;67(13):1432-8
pubmed: 17639504
Cancer Res. 2013 May 1;73(9):2795-805
pubmed: 23492366
Eur J Cancer. 2020 Sep;137:93-107
pubmed: 32750503
Oncogene. 2002 Oct 24;21(49):7497-506
pubmed: 12386812
Cell. 2014 Aug 28;158(5):1110-1122
pubmed: 25171411
J Biol Chem. 2016 Sep 2;291(36):18854
pubmed: 27591254
Cancer Res. 2005 Mar 15;65(6):2130-8
pubmed: 15781623
BMC Cancer. 2007 Apr 12;7:64
pubmed: 17430594
Breast Cancer Res. 2012 May 25;14(3):R86
pubmed: 22632416
Nat Rev Urol. 2012 Aug;9(8):418-28
pubmed: 22710668
Int J Cell Biol. 2012;2012:189521
pubmed: 22481945
Cancer Cell. 2013 Feb 11;23(2):159-70
pubmed: 23410972
Cancer Res. 2015 Mar 15;75(6):1021-34
pubmed: 25770290
Heart Vessels. 1997;Suppl 12:110-2
pubmed: 9476558
Am J Pathol. 2012 Aug;181(2):401-12
pubmed: 22705054
PLoS One. 2012;7(7):e42132
pubmed: 22860065
Cancer Biol Ther. 2007 Oct;6(10):1638-43
pubmed: 18245958
Clin Cancer Res. 2012 Mar 1;18(5):1364-73
pubmed: 22261809
Cancer Gene Ther. 2021 Jan 7;:
pubmed: 33414516
Endocr Pathol. 2001 Summer;12(2):125-36
pubmed: 11579678
Scand J Urol. 2016 Dec;50(6):420-424
pubmed: 27416104
Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15166-71
pubmed: 15353581
J Pathol. 2013 Sep;231(1):130-41
pubmed: 23794398
Mod Pathol. 2008 Nov;21(11):1371-8
pubmed: 18552821
J Cancer. 2019 Jun 2;10(12):2800-2810
pubmed: 31258788
Eur Urol. 2012 May;61(5):1019-24
pubmed: 22336380
Clin Cancer Res. 2014 Apr 1;20(7):1791-802
pubmed: 24526735
Genes Dev. 2000 Jun 1;14(11):1319-31
pubmed: 10837025
Cancer Cell. 2005 Nov;8(5):393-406
pubmed: 16286247
J Clin Oncol. 2004 Jul 15;22(14):2790-9
pubmed: 15254046
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
PLoS Genet. 2013;9(1):e1003180
pubmed: 23300485
World J Mens Health. 2013 Apr;31(1):36-46
pubmed: 23658864
Br J Cancer. 2005 Jun 20;92(12):2153-9
pubmed: 15942628
Clin Cancer Res. 2010 Mar 1;16(5):1553-60
pubmed: 20179235
Br J Cancer. 1999 Apr;79(11-12):1879-83
pubmed: 10206308
Cancers (Basel). 2020 Oct 18;12(10):
pubmed: 33081035
J Pathol. 1996 Apr;178(4):437-41
pubmed: 8691323
Clin Cancer Res. 2011 Sep 15;17(18):5878-88
pubmed: 21791629
J Cell Biol. 1996 Apr;133(1):199-209
pubmed: 8601608
Oncotarget. 2016 Jan 26;7(4):3897-904
pubmed: 26684029
J Cutan Pathol. 2000 Jan;27(1):24-9
pubmed: 10660128
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Carcinog. 2009;8:3
pubmed: 19240373
Am J Clin Pathol. 2006 Jan;125(1):119-26
pubmed: 16483000
Int J Oral Maxillofac Surg. 2006 Apr;35(4):356-61
pubmed: 16288849
BJU Int. 2002 Apr;89(6):538-42
pubmed: 11942960
Am J Surg Pathol. 2004 Jul;28(7):928-34
pubmed: 15223964